Though light on detail Enovis Corporation (ENOV), a medical device maker serving the reconstructive surgery, rehabilitation, pain management, and physical therapy verticals, revealed multiple federal agencies are scrutinizing its financial arrangements with health care providers.

The company disclosed in its latest annual report it has received subpoenas and other requests for information from state and federal agencies including, among unnamed others, the U.S. Department of Justice and the Office of Inspector General of the Department of Health and Human Services.

Enovis volunteered little detail other than:

“The requests and/or subpoenas we have received relate primarily to financial arrangements with health care providers, regulatory compliance and sale and/or product promotional practices.”

These matters were previously undisclosed as no mention of the investigations were made in the company’s previous three quarterly filings or the prior year’s annual report.

With an Enterprise Value (EV) of approximately $3.5 billion, Enovis is priced as if it will grow annual sales to more than $11.5 billion, up from an estimated $2.2 billion in 2025. To justify its current share price of $38.65 our Reverse DCF— which quantifies investor expectations embedded in the current share price— indicates Enovis must:

—Grow sales 22% annually between 2027-2034, significantly faster than the company’s estimated 2025 and 2026 sales growth of 5.2% and 6.3%, respectively, and the three-year average of 14.1%
—Immediately increase NOPAT margin to 7.7%, significantly higher than our 2024 estimate of (5.46%) and our 3-year average estimate of (2.61%)
—Increase Invested Capital (IC) Turns to 1.2 from our 3-year average estimate of 0.44

Notably, the current share price also implies Enovis increases Return on Invested Capital (ROIC) to 9.24% from our 3-year average estimate of (1.07%):